Plasma metabolomics profiles in rats with acute traumatic brain injury

• DOI: 10.1371/journal.pone.0182025
• Publication Date: 2017-08-03T17:44:10Z
• Authors: Fei Zheng; Zi-An Xia; Yi-Fu Zeng; Jie-Kun Luo; Peng Sun; Han-Jin Cui; Yang Wang; Tao Tang; Yan-Tao Zhou
• Keywords: Male; Science; Q; R; Rats; 3. Good health; Rats, Sprague-Dawley; 03 medical and health sciences; 0302 clinical medicine; Brain Injuries; Brain Injuries, Traumatic; Metabolome; Medicine; Animals; Metabolomics; Biomarkers; Research Article

Traumatic brain injury (TBI) is a major cause of mortality and disability worldwide. We validated the utility of plasma metabolomics analysis in the clinical diagnosis of acute TBI in a rat model of controlled cortical impact (CCI) using gas chromatography/mass spectrometry (GC/MS). Thirty Sprague-Dawley rats were randomly divided into two groups of 15 rats each: the CCI group and sham group. Blood samples were obtained from the rats within the first 24 h after TBI injury. GC/MS measurements were performed to evaluate the profile of acute TBI-induced metabolic changes, resulting in the identification of 45 metabolites in plasma. Principal component analysis, partial least squares-discriminant analysis, orthogonal partial least square discriminant analysis using hierarchical clustering and univariate/multivariate analyses revealed clear differences in the plasma metabolome between the acute CCI group and the sham group. CCI induced distinctive changes in metabolites including linoleic acid metabolism, amino acid metabolism, galactose metabolism, and arachidonic acid metabolism. Specifically, the acute CCI group exhibited significant alterations in proline, phosphoric acid, β-hydroxybutyric acid, galactose, creatinine, L-valine, linoleic acid and arachidonic acid. A receiver operating characteristic curve analysis showed that the above 8 metabolites in plasma could be used as the potential biomarkers for the diagnosis of acute TBI. Furthermore, this study is the first time to identify the galactose as a biomarker candidate for acute TBI. This comprehensive metabolic analysis complements target screening for potential diagnostic biomarkers of acute TBI and enhances predictive value for the therapeutic intervention of acute TBI.